石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01093 石药集团

未开盘 09-14 16:08:04

8.865

+0.155

+1.78%

最高8.890	最低8.520	成交量9,591万
今开8.580	昨收8.710	日振幅4.25%
总市值1,021亿	流通市值1,021亿	总股本115.22亿
成交额8.39亿	换手率0.83%	流通股本115.22亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01093","market":"HK","secType":"STK","nameCN":"石药集团","latestPrice":8.865,"timestamp":1789373284002,"preClose":8.71,"halted":0,"volume":95912466,"delay":0,"changeRate":0.017795637198622198,"floatShares":11522000000,"shares":11522000000,"eps":0.3972435612656282,"marketStatus":"未开盘","change":0.155,"latestTime":"09-14 16:08:04","open":8.58,"high":8.89,"low":8.52,"amount":839322080,"amplitude":0.04248,"askPrice":8.865,"askSize":494000,"bidPrice":8.86,"bidSize":22000,"shortable":3,"etf":0,"ttmEps":0.7604829334007877,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789435800000},"marketStatusCode":0,"adr":0,"listingDate":772128000000,"exchange":"SEHK","adjPreClose":8.71,"dividendRate":0.038062,"openAndCloseTimeList":[[1789349400000,1789358400000],[1789362000000,1789372800000]],"volumeRatio":0.830041532907661,"optionData":{"bulkOrders":[{"symbol":"CSP.HK","call":true,"expireDate":1790611200000,"strike":"9.25","timestamp":1789371977044,"price":0.19,"volume":300,"amount":114000,"type":"*"},{"symbol":"CSP.HK","call":true,"expireDate":1790611200000,"strike":"9.75","timestamp":1789351140962,"price":0.07,"volume":226,"amount":31640,"type":"*"}]},"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"CSP.HK","impliedVol":0.5,"impliedVolPercentile":0.4163},"requestUrl":"/m/hq/s/01093/wiki","defaultTab":"wiki","newsList":[{"id":"2667269654","title":"石药集团(01093.HK)：SYS 6010联合恩朗苏拜单抗用于治疗未经系统性治疗的驱动基因阴性晚期NSCLC的I / II期临床研究数据于2026年世界肺癌大会(WCLC)上以口头报告形式公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2667269654","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667269654?lang=zh_cn&edition=full","pubTime":"2026-09-14 17:34","pubTimestamp":1789378468,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2039709279.SGD","01093","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","LU0501845795.SGD","IE0008368742.USD","LU1226288170.HKD","IE00B031HY20.USD","LU0326950275.SGD","LU0140636845.USD","LU1152091168.USD","LU1993786604.SGD","BK1515","LU1152091754.HKD","LU1226287529.USD","LU1226288253.USD","LU1328277881.USD","IE0008369823.USD","LU1813983027.USD","IE00B5MMRT66.SGD","LU0314109678.HKD","BK1521","LU1226287792.SGD","IE00B543WZ88.USD","LU0315179316.USD","LU0072913022.USD","LU1226287875.USD","BK1191","IE00BZ08YS42.EUR","LU1807302812.USD","KURE","SG9999004220.SGD","LU1008478684.HKD","LU1951186391.HKD","LU0880133367.SGD","LU1960683339.HKD","LU0067412154.USD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666510786","title":"港股异动 | 创新药概念股持续调整 海外利率预期反复 2026国谈收官进入结果等待期","url":"https://stock-news.laohu8.com/highlight/detail?id=2666510786","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666510786?lang=zh_cn&edition=full","pubTime":"2026-09-11 11:08","pubTimestamp":1789096112,"startTime":"0","endTime":"0","summary":"消息面上，2026国谈现场谈判和价格协商收官，正式进入结果等待期。新版国家基本医保药品目录与商保创新药目录预计11月正式公布，2027年1月1日起统一执行。此外，能源供给风险急剧升温，10年期美债收益率攀升至近三年高位，市场定价美联储下周加息25BP的概率已升至约70%。分析人士指出，近期创新药板块的调整，主要受到海外利率预期反复、油价上行推升通胀担忧、临床风险事件扰动及资金风格轮动等因素影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494833.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU1813983027.USD","BK4585","LNGR","LU0326950275.SGD","LU2097828805.USD","LU2097828557.USD","LU0501845795.SGD","BK1191","LU1226287875.USD","MCRO","LU1188198961.HKD","LU0067412154.USD","KURE","IBBQ","LU0455707207.USD","01801","LU1328277881.USD","BK1515","LU0149534421.HKD","LU0244354667.USD","LU1226287792.SGD","WRTH","LU0072913022.USD","02157","LU2242644610.SGD","LU2097828474.EUR","06978","LU1807302812.USD","IE0008369823.USD","09995","159992","MEDX","LU2488822045.USD","LU1831875114.USD","IE0008368742.USD","01093","KCAI","LU1960683339.HKD","BK1589","LU0880133367.SGD","LU1008478684.HKD","VXUS","IE00BZ08YS42.EUR","LU2328871848.SGD","PEVC","LU1226288170.HKD","LU1969619763.USD","IE00BZ08YT58.USD","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170631576","title":"全球股市综述：市场快讯","url":"https://stock-news.laohu8.com/highlight/detail?id=1170631576","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170631576?lang=zh_cn&edition=full","pubTime":"2026-09-10 15:28","pubTimestamp":1789025335,"startTime":"0","endTime":"0","summary":"分析师称，在出席巴克莱全球必需消费品大会并听取首席执行官Fernando Fernandez及印度斯坦联合利华首席执行官Priya Nair的发言后，联合利华或将成为仅次于欧莱雅的增速最快的必需消费品企业。野村将目标价从18,500日圆上调至20,000日圆，维持买入评级。该股上涨2.4%，报15,670日圆。星展恢复对该股的覆盖，给予买入评级，目标价13.70港元。该公司表示，与国内市场不同，昆士兰人口持续增长，而长期住房供应短缺已成为严峻社会问题。该股下跌0.4%，报31.60港元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345776255.USD","SG9999013353.USD","UN","LU0886674414.USD","SG9999014492.USD","LU0594300179.USD","LU0251144936.SGD","LU0320764755.SGD","SG9999006266.SGD","SG9999008742.SGD","SGXZ27511609.SGD","LU0072913022.USD","SG9999002604.SGD","LU0588545730.USD","SGXZ58947870.SGD","LU0210637038.USD","LU0630378429.USD","LU1008478684.HKD","IE00B543WZ88.USD","LU2506952097.USD","LU0096374516.USD","LU1960683339.HKD","SG9999013460.SGD","LU0737861699.HKD","LU0577902298.EUR","BK1521","LU0831103253.SGD","LU2506951958.HKD","LU0689626769.HKD","SG9999001226.SGD","SG9999001903.USD","LU2257852520.SGD","SG9999003925.USD","LU0084288322.USD","LU0029875118.USD","LU0192582467.USD","LU0315179316.USD","LU0878005551.USD","LU1328615791.USD","LU0955648018.USD","SG9999013478.USD","LU0043850808.USD","LU0329678170.USD","LU0865486749.SGD","BK4183","LU0955623706.USD","LU0955669360.SGD","LU2226123227.USD","LU0140636845.USD","LU1282649810.SGD","IE00BHRH8C09.USD","LU0188438112.USD","LU0650527681.SGD","LU2226123490.SGD","SG9999016042.SGD","SG9999009443.AUD","LU0543330483.HKD","IE0031814969.USD","SG9999000475.SGD","BK6523","LU2506952170.USD","LU1807302812.USD","LU0048597586.USD","BK4585","LU0950375773.USD","IE0008369823.USD","SG9999001846.SGD","SG9999000343.SGD","LU0326950275.SGD","LU0823417737.USD","SGXZ24219693.SGD","LU0823413587.USD","BK1534","LU0384037296.USD","SG9999002620.SGD","IE00BVYPNQ40.USD","SG9999004220.SGD","LU0672654166.SGD","BK6112","LU1497733631.SGD","IE00BZ08YR35.GBP","LU0823397285.USD","LU0261947096.USD","LU0197773160.USD","LU0235996351.USD","LU0880133367.SGD","BK1258","SGXZ43160589.SGD","SG9999003800.SGD","LU0577902454.USD","IE0003895053.USD","LU0441854154.USD","LU0441851309.USD","LU0605514214.HKD","LU0488056044.USD","LU0737861269.HKD","LU0345775950.USD","LU0197773673.USD","LU1226288253.USD","HK0000165453.HKD","LU1316543674.SGD","LU1224709979.USD","LU1956131251.USD","LU0971096721.USD","LU1226287792.SGD","D05.SI","LU0211331839.USD","LU0501845795.SGD","LU0856984785.SGD","LU0577902611.USD","LU0630378692.HKD","LU0873338254.USD","LU1522347837.USD","SG9999004360.SGD","IE00BZ08YT58.USD","LU0819123356.HKD","BK4592","01997","LU0205439572.USD","LU1152091754.HKD","LU1328277881.USD","LU0124676726.USD","SGXZ70427877.SGD","IE00BG0RBZ43.SGD","IE00BGHQDM52.EUR","LU0823038988.USD","SGXZ91733576.SGD","LU0878004406.USD","BK1229","CAOVY","LU1839390173.USD","LU0882747503.HKD","LU1152091168.USD","LU3227948356.SGD","SG9999001135.SGD","SG9999001127.SGD","BK4588","00688","LU0314109678.HKD","LU0128522157.USD","LU1497734951.SGD","SG9999002406.SGD","BK1240","LU2506951875.HKD","IE0008368742.USD","IE00BZ08YS42.EUR","LU0165289439.USD","LU0588545490.SGD","LU0588545904.SGD","LU0819121731.USD","SG9999002679.SGD","LU0831093199.SGD","03121","LU0823397103.USD","LU1226287529.USD","LU1211504680.USD","LU2237957811.SGD","LU0577902371.SGD","LU0261945553.USD","SG9999010078.USD","IE00BHRH8D16.HKD","LU0675040207.SGD","LU1282649067.USD","LU0326948709.USD","LU0173614495.USD","LU0251143029.SGD","SG9999002562.SGD","LU0737861772.HKD","LU0532188223.SGD","LU0762540952.USD","SG9999009997.SGD","LU1226288170.HKD","LU0823039010.USD","SG9999000459.SGD","LU1993786604.SGD","LU2152927971.USD","LU2039709279.SGD","LU1363072403.SGD","LU1130305938.SGD","SG9999014302.SGD","LU1634259391.SGD","SG9999010052.SGD","LU0823413660.USD","LU0287142896.SGD","LU0557290698.USD","SGXZ16066938.SGD","ULVR.UK","01093","LU1497733557.USD","LU1813983027.USD","SG9999003826.SGD","SG9999013486.USD","IE00BVYPNP33.GBP","LU0329678337.USD","LU0169518387.USD","SG9999014484.SGD","IE00B031HY20.USD","LU2237957902.USD","LU1504937902.USD","LU0648948544.HKD","BK1191","BK1515","LU0577902538.SGD","LU2238330802.EUR","LU1770036033.HKD","SG9999007991.SGD","LU0823417653.USD","LU0048573645.USD","LU0594300419.USD","IE00BKZH1Z71.USD","LU1951186391.HKD","LU1282649141.HKD","LU1634259557.SGD","SG9999005177.SGD","LU0067412154.USD","LU0315178854.USD","SGXZ51708014.SGD","UL","LU0229494975.USD","BK6516","LU1226287875.USD","BK1601","SG9999002414.USD","IE00B5MMRT66.SGD","SG9999011175.SGD","LU0011963245.USD","LU0061477393.USD","BK1555","KURE","LU0898667661.SGD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2666568197","title":"大行评级丨里昂：重申石药“高确信跑赢大市”评级，股价急挫创造入市机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2666568197","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666568197?lang=zh_cn&edition=full","pubTime":"2026-09-10 14:47","pubTimestamp":1789022823,"startTime":"0","endTime":"0","summary":"石药集团与阿斯利康合作开发口服Lp项目YS2302018，目前正处于第一期临床阶段。该行指，市场亦流传关于石药集团旗下恩必普在国家医保目录续期结果不利的消息。就此，该行已向公司确认，价格调整幅度可控。里昂认为，HORIZON作为首个Lp结果研究的失败，并不会立即推翻Lp预测。石药集团股价急挫带来具吸引力的入市机会，重申对其“高确信跑赢大市”评级，目标价19港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260910/32365939.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666550223","title":"港股异动 | 石药集团(01093)跌超4% Lp(a)HORIZON研究受阻或对包括公司在内的参与者构成压力","url":"https://stock-news.laohu8.com/highlight/detail?id=2666550223","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666550223?lang=zh_cn&edition=full","pubTime":"2026-09-10 14:13","pubTimestamp":1789020819,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，石药集团跌超4%，截至发稿，跌2.69%，报8.855港元，成交额9.38亿港元。里昂发布研报称，诺华行政总裁最新对LpHORIZON研究的评论，可能将研究失败归因于晚期降低Lp相较于基因的终身Lp暴露，所带来的心血管益处有限，这将对包括石药集团在内的中国内地Lp参与者构成压力。里昂认为，HORIZON作为首个Lp结果研究的失败，并不会立即推翻Lp预测。另一方面，石药集团股价急挫带来具吸引力的入市机会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494328.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0008369823.USD","LU0067412154.USD","LU2039709279.SGD","LU1226287792.SGD","HK0000165453.HKD","LU1226287875.USD","IE00B5MMRT66.SGD","IE00B031HY20.USD","01093","BK4588","LU1226288253.USD","IE00B543WZ88.USD","LU0140636845.USD","LU1226288170.HKD","LU1993786604.SGD","LU1152091168.USD","LU0880133367.SGD","SG9999004220.SGD","KCAI","LU1960683339.HKD","LU0501845795.SGD","BK1191","LU0072913022.USD","IE00BZ08YT58.USD","LU1813983027.USD","VXUS","BK4585","LU1226287529.USD","LU0326950275.SGD","LU1152091754.HKD","IE00BZ08YR35.GBP","LU1328277881.USD","LU1951186391.HKD","LU0314109678.HKD","BK1515","KURE","IE0008368742.USD","LU0315179316.USD","LU1807302812.USD","LU1008478684.HKD","IE00BZ08YS42.EUR","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666550551","title":"里昂：重申石药集团(01093.HK)“高确信跑赢大市”评级 目标价19港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666550551","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666550551?lang=zh_cn&edition=full","pubTime":"2026-09-10 14:00","pubTimestamp":1789020018,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00B543WZ88.USD","IE0008368742.USD","LU1960683339.HKD","BK1515","LU1152091754.HKD","IE00BZ08YS42.EUR","LU0315179316.USD","LU1993786604.SGD","LU1951186391.HKD","IE00BZ08YR35.GBP","IE0008369823.USD","LU0880133367.SGD","IE00B031HY20.USD","HK0000165453.HKD","KURE","LU1226287529.USD","LU1226288253.USD","01093","LU1152091168.USD","LU2039709279.SGD","BK1521","IE00BZ08YT58.USD","LU1807302812.USD","SG9999004220.SGD","LU1008478684.HKD","LU0067412154.USD","LU0140636845.USD","LU0314109678.HKD","LU0501845795.SGD","LU1813983027.USD","IE00B5MMRT66.SGD","LU1226287875.USD","LU1328277881.USD","BK1191","LU0072913022.USD","LU1226287792.SGD","LU1226288170.HKD","LU0326950275.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191841564","title":"异动解读｜石药集团盘中下跌3.3%，医药板块整体承压延续调整","url":"https://stock-news.laohu8.com/highlight/detail?id=1191841564","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191841564?lang=zh_cn&edition=full","pubTime":"2026-09-10 10:15","pubTimestamp":1789006544,"startTime":"0","endTime":"0","summary":"9月10日，石药集团盘中下跌3.3%，报8.8港元，成交额2.19亿港元。消息面上，全球股市近日出现集体调整，欧洲主要股指开盘下跌、日韩股市连续收跌，避险情绪蔓延持续拖累港股医药板块。同行业个股普遍走弱，翰森制药跌2.18%、中国生物制药跌2.14%、恒瑞医药跌2.66%、复星医药跌4.05%、四环医药跌3.87%，板块整体承压。此外，此前汇添富基金以每股均价约9.75港元减持石药集团约3912万股，持股比例由5.27%降至4.93%，机构减持动向或对短期情绪构成压力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"石药集团盘中下跌，医药板块承压调整","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666128556","title":"【券商聚焦】中信证券：中国创新药进入全球价值兑现阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2666128556","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666128556?lang=zh_cn&edition=full","pubTime":"2026-09-10 08:59","pubTimestamp":1789001960,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研究指，2026年以来，中国创新药国内市场快速放量，从中报来看头部创新药企业在新产品驱动下，创新药收入快速增长，biopharma陆续进入盈利拐点；出海创新药开始进入三期/注册研究兑现阶段；近期多个国际学术大会将至，众多创新药管线进入密集的数据催化期。该机构认为中国创新药进入全球价值兑现阶段，建议关注：①头部国际化创新药企业有望迎来产品全球价值兑现期；②头部创新药企业产品放量进入新的成长阶段；③具有全球潜力的管线资产国际化有望加速兑现。综上，我们维持创新药行业“强于大市”评级。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991210","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064130708.USD","02616","01093","600030","BK1141","LU1997245177.USD","IE00B543WZ88.USD","LU1226287792.SGD","SG9999004220.SGD","LU1720050803.USD","LU1255011170.USD","LU0572944931.SGD","09995","02269","KCE","LU2039709279.SGD","BK0028","09688","LU0561508036.HKD","LU0463099449.HKD","LU1226287875.USD","BK1161","LU2580892862.HKD","LU1580142542.USD","LU0417516738.SGD","01877","01177","LU0516422952.EUR","LU1880383366.USD","LU1969619763.USD","KURE","02142","06185","LU0348783233.USD","01801","LU1655091616.SGD","LU0979878070.USD","06160","LU0181495838.USD","LU1794554557.SGD","LU0819121731.USD","LU0405327494.USD","IE0008369823.USD","LU1813983027.USD","LU1820825898.SGD","LU2148510915.USD","09926","LU0348825331.USD","06030","LU1961090484.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146103883","title":"石药集团（01093）戈舍瑞林缓释注射液SYH 9102获中国临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1146103883","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146103883?lang=zh_cn&edition=full","pubTime":"2026-09-09 18:11","pubTimestamp":1788948671,"startTime":"0","endTime":"0","summary":"2026年9月9日，石药集团有限公司发布自愿公告称，其自主研发的促性腺激素释放激素受体激动剂——戈舍瑞林缓释注射液已获国家药品监督管理局批准在中国开展临床试验。据公告，SYH 9102为全球首款获批开展临床试验的即用型戈舍瑞林缓释注射液。此次获批的临床适应症为治疗实体瘤患者。公告同时指出，SYH 9102亦可应用于子宫内膜异位症等雌激素依赖性疾病领域，具备进一步开发潜力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134024208","title":"石药集团（01093）罗替高汀长效注射液获批在中国开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1134024208","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134024208?lang=zh_cn&edition=full","pubTime":"2026-09-09 18:11","pubTimestamp":1788948669,"startTime":"0","endTime":"0","summary":"2026年9月9日，石药集团有限公司公告称，其开发的多巴胺受体激动剂罗替高汀长效注射液已获国家药品监督管理局批准在中国开展临床试验。该产品成为国内首个获准临床的皮下注射罗替高汀长效制剂。公告显示，SYH 9087注射液基于公司长效递送技术平台，采用皮下注射形成原位药物贮库，每周给药一次。董事会主席蔡东晨在公告中代董事会发布上述信息。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666846135","title":"石药集团(01093)：戈舍瑞林缓释注射液(SYH9102注射液)在中国获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2666846135","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666846135?lang=zh_cn&edition=full","pubTime":"2026-09-09 18:09","pubTimestamp":1788948562,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，本集团开发的促性腺激素释放激素受体激动剂戈舍瑞林缓释注射液(该产品)已获中国国家药品监督管理局批准，可在中国开展临床试验。该产品为全球首款获批临床的即用型戈舍瑞林缓释注射液，可通过与垂体GnRH受体高亲和力结合并诱导受体降调节，抑制促性腺激素分泌，降低血清睾酮及雌二醇水平，实现药物去势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493973.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B5MMRT66.SGD","LU0314109678.HKD","01093","BK1515","IE00BZ08YR35.GBP","LU1226287792.SGD","IE00B031HY20.USD","LU1328277881.USD","PSYK","LU1813983027.USD","SG9999004220.SGD","IE00BZ08YS42.EUR","IE00B543WZ88.USD","IE0008368742.USD","LU1008478684.HKD","LU0326950275.SGD","LU1993786604.SGD","LU0880133367.SGD","LU1226287875.USD","BK1191","LU1152091754.HKD","LU0315179316.USD","LU1807302812.USD","LU1226288253.USD","LU2039709279.SGD","LU0140636845.USD","HK0000165453.HKD","LU1960683339.HKD","BMED","LU1226287529.USD","LU1226288170.HKD","IE00BZ08YT58.USD","BK1521","LU0072913022.USD","LU0067412154.USD","MDTX","IBBQ","KURE","LU1951186391.HKD","LU1152091168.USD","IBBJ","IE0008369823.USD","LU0501845795.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184219055","title":"石药集团戈舍瑞林缓释注射剂（SYH9102）获中国临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1184219055","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184219055?lang=zh_cn&edition=full","pubTime":"2026-09-09 18:08","pubTimestamp":1788948506,"startTime":"0","endTime":"0","summary":"石药集团宣布，其研发的戈舍瑞林缓释注射剂已正式获得中国国家药品监督管理局的临床试验批准。石药集团此次获批的缓释剂型，旨在提供更持久的药物释放效果，有望改善患者的治疗体验和依从性。获得临床试验批准后，石药集团将按照相关法规和伦理要求，组织开展一系列临床试验，以评估该注射剂的安全性、有效性和药代动力学特性。石药集团表示，将积极推进该产品的临床研发进程，并严格遵守国家药品监管的相关规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0315179316.USD","LU1226287529.USD","LU0326950275.SGD","LU0501845795.SGD","IE0008368742.USD","LU0880133367.SGD","IE00B031HY20.USD","LU0314109678.HKD","LU1328277881.USD","LU1813983027.USD","LU0067412154.USD","IE00BZ08YS42.EUR","LU0072913022.USD","LU1226288253.USD","LU1008478684.HKD","LU1951186391.HKD","IE00B543WZ88.USD","HK0000165453.HKD","BK1515","LU1226287792.SGD","IE00BZ08YR35.GBP","LU0140636845.USD","LU2039709279.SGD","LU1226287875.USD","SG9999004220.SGD","IE0008369823.USD","01093","LU1226288170.HKD","LU1807302812.USD","LU1152091168.USD","LU1960683339.HKD","BK1191","LU1993786604.SGD","KURE","IE00BZ08YT58.USD","BK1521","LU1152091754.HKD","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152287892","title":"异动解读｜石药集团盘中下跌3.03%，全球股市集体调整拖累医药板块","url":"https://stock-news.laohu8.com/highlight/detail?id=1152287892","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152287892?lang=zh_cn&edition=full","pubTime":"2026-09-09 13:12","pubTimestamp":1788930722,"startTime":"0","endTime":"0","summary":"9月9日，石药集团盘中下跌3.03%，报9.135港元，成交额3.87亿港元。消息面上，近日全球股市出现集体调整，欧洲主要股指开盘下跌、日韩股市连续收跌，避险情绪蔓延拖累港股。同行业中，中国生物制药跌1.88%，和黄医药跌1.18%，板块整体承压。公司层面，石药集团近期利好密集：SYH2083滴眼液获批临床、SYS6010第四次获纳入突破性治疗品种名单、SYH2085流感药II期临床启动，多家投行维持买入评级并上调目标价至11.2至14港元区间，基本面并无明显利空。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"石药集团随大盘回调，创新药管线利好密集","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158798070","title":"石药集团（01093）SYH2083滴眼液获中国临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1158798070","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158798070?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:51","pubTimestamp":1788861116,"startTime":"0","endTime":"0","summary":"2026年9月8日，石药集团（01093）发布自愿公告称，公司自主研发的化药1类创新药SYH2083滴眼液已获国家药品监督管理局批准在中国开展临床试验。\nSYH2083是一款具有新型作用机制的小分子眼用制剂，可通过减少T淋巴细胞的黏附和激活、降低促炎信号，用于治疗眼表炎症相关疾病。临床前研究显示，该药在小鼠干眼模型中表现出显著药效活性，作用机制明确。\n本次获批的临床试验适应症为干眼症；公司同时表示，SYH2083未来亦具备向过敏性结膜炎等其他炎症性眼表疾病拓展的潜力。\n石药集团指出，此次临床试验获批将进一步丰富公司在眼科领域的创新药产品管线。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665131464","title":"第4项！石药EGFR ADC拟纳入突破性疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2665131464","media":"医药魔方","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665131464?lang=zh_cn&edition=full","pubTime":"2026-09-07 20:24","pubTimestamp":1788783840,"startTime":"0","endTime":"0","summary":"9月7日，CDE官网显示，石药集团的SYS6010拟纳入突破性疗法，用于免疫及含铂化疗治疗失败的复发或转移性驱动基因阴性非鳞非小细胞肺癌。SYS6010为石药创新制药旗下子公司巨石生物开发的一款EGFR ADC，由人源化抗EGFR单克隆抗体通过可裂解连接子与拓扑异构酶I抑制剂载荷偶联而成。2026年8月，SYS6010治疗EGFR-TKI治疗失败的EGFR突变型局部晚期或转移性NSCLC的III期研究达到主要终点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-07/doc-iniqzhfq9563252.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["KURE","LU0072913022.USD","LU1993786604.SGD","BK1521","01093","LU0326950275.SGD","LU1807302812.USD","BK1191","LU1226287529.USD","IE0008368742.USD","LU0880133367.SGD","LU1226288170.HKD","LU1008478684.HKD","LU1226287792.SGD","LU1226287875.USD","IE00BZ08YS42.EUR","IE0008369823.USD","LU1328277881.USD","SG9999004220.SGD","LU1813983027.USD","LU0140636845.USD","LU0501845795.SGD","IE00B543WZ88.USD","LU1960683339.HKD","LU1152091754.HKD","LU1152091168.USD","LU1226288253.USD","HK0000165453.HKD","LU1951186391.HKD","IE00BZ08YT58.USD","LU0315179316.USD","IE00BZ08YR35.GBP","LU0067412154.USD","LU0314109678.HKD","BK1515","IE00B031HY20.USD","LU2039709279.SGD","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665319978","title":"石药集团(01093)：SYH2085片用于治疗成人单纯性流感的II期临床试验在中国正式启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319978","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665319978?lang=zh_cn&edition=full","pubTime":"2026-09-07 19:30","pubTimestamp":1788780616,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团开发的SYH2085片用于治疗成人无并发症的单纯性流行性感冒的II期临床试验已于中国首家中心正式启动。此前，集团已于2025年12月获中国国家药品监督管理局就该产品签发的《药物临床试验批准通知书》。本次启动的该产品临床试验为多中心、随机、双盲、安慰剂对照的II期临床研究，旨在评价该产品治疗中国成人无并发症的单纯性流行性感冒参与者中的有效性及安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492970.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0326950275.SGD","IE00BZ08YS42.EUR","LU1226287875.USD","LU0314109678.HKD","01093","IE0008368742.USD","BK1191","LU1226287792.SGD","LU1807302812.USD","IBBJ","LU1951186391.HKD","SG9999004220.SGD","IE0008369823.USD","KURE","LU1813983027.USD","IE00B031HY20.USD","LU1226288170.HKD","IE00BZ08YT58.USD","LU1993786604.SGD","IBBQ","PSYK","LU1152091754.HKD","HK0000165453.HKD","LU2039709279.SGD","LU0140636845.USD","LU1226287529.USD","BK1521","LU1960683339.HKD","MDTX","LU0067412154.USD","LU0315179316.USD","IE00B543WZ88.USD","LU0880133367.SGD","LU1226288253.USD","BMED","LU1152091168.USD","LU0072913022.USD","IE00B5MMRT66.SGD","LU0501845795.SGD","LU1328277881.USD","BK1515","LU1008478684.HKD","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664238859","title":"【券商聚焦】交银国际：医药行业收入稳健增长 多重利好推动盈利表现显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2664238859","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664238859?lang=zh_cn&edition=full","pubTime":"2026-09-04 09:00","pubTimestamp":1788483634,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，1H26港股/A股医药行业整体收入增长4.7%/3.2%。创新药产业链增速领跑行业，服务板块复苏：1）港股/A股CXO收入整体增长29.2%/25.3%，（扣非）净利润增长23.4%/67.6%，在各子板块中增速最快，行业整体景气度和订单需求处于高位。2）核心成药板块收入增长17.8%/3.4%、利润增长62.7%/35.0%。其中生物药增速远超化药，在板块收入中的占比也进一步提升。3）医院、器械、诊断、疫苗等板块业绩有复苏趋势。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990646","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952","01801","01951","09996","LU0327786744.USD","03759","02162","06990","02269","00013","03692","09966","03329","LU1152091168.USD","02596","LU1242518857.USD","01093","LU0307460666.USD","BK1161","06160","LU0039217434.USD","IE00B543WZ88.USD","01177","06078","09926","LU1880383366.USD","LU0588546209.SGD","LU2543165471.USD","01276","BK1589","01530","02268","LU0315179316.USD","LU0856984785.SGD","06821","02273","BK1209","KURE","BK1515","HK0000320264.USD","HK0000306685.HKD","02096","06996","LU0348783233.USD","LU1251922891.USD","01548","IE00B0JY6N72.USD","KCE","IE00B5MMRT66.SGD","SG9999004220.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664870226","title":"【生物医药小白投研】第八篇：小白完整投研框架与体系复盘","url":"https://stock-news.laohu8.com/highlight/detail?id=2664870226","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664870226?lang=zh_cn&edition=full","pubTime":"2026-09-03 16:10","pubTimestamp":1788423000,"startTime":"0","endTime":"0","summary":"经过前七篇的认知、排雷、管线、赛道、BD、估值、交易节奏全维度学习，本篇作为专栏终章，复盘整套投研体系，整合核心知识点，帮助新手建立系统化的投资决策习惯。对仅有纸面高额交易额、低首付、小公司噱头BD的标的保持警惕。作者丨吴言编辑丨Jasmine往期推荐:第七篇：看得懂基本面，更要把握交易节奏第六篇：小白也能上手的医药股估值与前景打分体系第五篇：读懂BD的价值逻辑第四篇：分清黄金赛道与内卷红海","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzI2MDAzMTQ4OA==&mid=2650514079&idx=1&sn=b343b5c979b09868c5b4b6ffa6bf3616&chksm=f3613873bcb2e49ac858ccd3d88ca34c5f10e2143037b5c049e758da1d990257cd4b54d9d0b6&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["LU2097828631.EUR","BK1500","BK1515","LU0067412154.USD","KURE","LU1251922891.USD","LU0880133367.SGD","LU1960683339.HKD","LU0828237510.HKD","LU1813983027.USD","SG9999004220.SGD","LU0348735423.USD","02269","LU0455707207.USD","LU0856984785.SGD","03692","LU0359202008.SGD","LU1880383366.USD","LU1720050803.USD","IE00BZ08YT58.USD","LU2488822045.USD","LU2097828474.EUR","IE00B0JY6N72.USD","LU1794554557.SGD","01801","LU0181495838.USD","LU0320764599.SGD","06160","HK0000165453.HKD","LU1807302812.USD","LU0359201612.USD","LU1008478684.HKD","LU2039709279.SGD","LU1328277881.USD","LU0244354667.USD","LU0051755006.USD","LU1188198961.HKD","LU0128526141.USD","LU1969619763.USD","BK1583","LU0456846285.SGD","01530","BK1588","LU0072913022.USD","LU0516423174.USD","01093","LU0029874061.USD","LU2242644610.SGD","LU0572944931.SGD","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664823065","title":"港股异动 | 石药集团(01093)涨超4% SYS6010近日再获国家药监局纳入突破性治疗品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2664823065","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664823065?lang=zh_cn&edition=full","pubTime":"2026-09-03 11:14","pubTimestamp":1788405245,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，石药集团涨超4%，截至发稿，涨4.09%，报9.545港元，成交额7.59亿港元。消息面上，石药集团发布公告，本集团开发的SYS6010(该产品)近日再获中国国家药品监督管理局纳入突破性治疗品种名单，拟定适应症为既往接受过免疫及含铂化疗治疗失败的复发或转移性头颈鳞癌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491361.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0326950275.SGD","LU0501845795.SGD","LU1226288170.HKD","IE00BZ08YT58.USD","LU0072913022.USD","SG9999004220.SGD","LU1152091754.HKD","LU1328277881.USD","LU1993786604.SGD","VXUS","LU2039709279.SGD","LU1008478684.HKD","IE00B543WZ88.USD","IE00BZ08YR35.GBP","LU1960683339.HKD","LU0880133367.SGD","01093","LU1813983027.USD","LU1152091168.USD","BK1521","IE00B031HY20.USD","BK4588","LU0314109678.HKD","BK1191","BK1515","LU0315179316.USD","LU1226288253.USD","IE0008368742.USD","HK0000165453.HKD","IE00BZ08YS42.EUR","LU1951186391.HKD","LU0067412154.USD","KCAI","LU1226287529.USD","LU1226287875.USD","LU0140636845.USD","IE00B5MMRT66.SGD","LU1226287792.SGD","LU1807302812.USD","KURE","BK4585","IE0008369823.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664231028","title":"创新药企密集进入临床数据验证期，石药集团涨超4%！华宝基金港股通创新药ETF（520880）再收半年线！","url":"https://stock-news.laohu8.com/highlight/detail?id=2664231028","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664231028?lang=zh_cn&edition=full","pubTime":"2026-09-03 10:52","pubTimestamp":1788403920,"startTime":"0","endTime":"0","summary":"9月3日，港股创新药链继续活跃，创新药龙头公司领涨，石药集团、中国生物制药双双涨超4%。纯正创新药指数——恒生港股通创新药精选指数一度冲高逾2%，跟踪该指数的港股通创新药ETF华宝盘中再收半年线。中金公司提示，创新药较多公司进入临床数据验证阶段，值得自下而上关注。据统计，港股通创新药ETF华宝覆盖的48家创新药研发公司中，31家上半年实现盈利，归母净利同比正增长的有33家，占比近7成。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-03/doc-iniqpkry1034045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2039709279.SGD","01093","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","LU0501845795.SGD","IE0008368742.USD","LU1226288170.HKD","IE00B031HY20.USD","LU0326950275.SGD","LU0140636845.USD","LU1152091168.USD","LU1993786604.SGD","BK1515","IBBQ","LU1152091754.HKD","LU1226287529.USD","159992","LU1226288253.USD","LU1328277881.USD","IE0008369823.USD","LNGR","LU1813983027.USD","IE00B5MMRT66.SGD","LU0314109678.HKD","BK1521","LU1226287792.SGD","IE00B543WZ88.USD","LU0315179316.USD","520880","LU0072913022.USD","BK1161","LU1226287875.USD","FLHK","BK1191","IE00BZ08YS42.EUR","159316","LU1807302812.USD","KURE","SG9999004220.SGD","LU1008478684.HKD","06978","LU1951186391.HKD","LU0880133367.SGD","LU1960683339.HKD","LU0067412154.USD","MEDX","HK0000165453.HKD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cspc.com.hk","stockEarnings":[{"period":"1week","weight":-0.0842},{"period":"1month","weight":0.0201},{"period":"3month","weight":0.2801},{"period":"6month","weight":-0.0137},{"period":"1year","weight":-0.1108},{"period":"ytd","weight":0.0752}],"compareEarnings":[{"period":"1week","weight":-0.0195},{"period":"1month","weight":-0.0079},{"period":"3month","weight":0.0173},{"period":"6month","weight":-0.0426},{"period":"1year","weight":-0.0557},{"period":"ytd","weight":-0.0278}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"石药集团有限公司是一家主要从事药品的生产及销售的公司。该公司主要从事成药业务、原料产品业务、功能食品及其他业务。该公司的产品主要涵盖神经系统、抗肿瘤、抗感染、心血管、呼吸系统、消化代谢以及其他治疗领域。该公司的产品销往国内外市场。","yearOnYearQuotes":[{"month":1,"riseRate":0.53125,"avgChangeRate":0.009625},{"month":2,"riseRate":0.75,"avgChangeRate":0.094313},{"month":3,"riseRate":0.46875,"avgChangeRate":0.017543},{"month":4,"riseRate":0.59375,"avgChangeRate":0.057684},{"month":5,"riseRate":0.59375,"avgChangeRate":0.042479},{"month":6,"riseRate":0.3125,"avgChangeRate":0.001853},{"month":7,"riseRate":0.393939,"avgChangeRate":0.015989},{"month":8,"riseRate":0.454545,"avgChangeRate":0.011919},{"month":9,"riseRate":0.484848,"avgChangeRate":-0.000906},{"month":10,"riseRate":0.5625,"avgChangeRate":0.01001},{"month":11,"riseRate":0.46875,"avgChangeRate":0.006831},{"month":12,"riseRate":0.5,"avgChangeRate":-0.013329}],"exchange":"SEHK","name":"石药集团","nameEN":"CSPC PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石药集团,01093,石药集团股票,石药集团股票老虎,石药集团股票老虎国际,石药集团行情,石药集团股票行情,石药集团股价,石药集团股市,石药集团股票价格,石药集团股票交易,石药集团股票购买,石药集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}